HER2-positive Metastatic Breast Cancer, Oligometastatic Disease
Conditions
Keywords
HER2-positive, Breast cancer, Oligometastatic
Brief summary
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT. The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT followed by the administration of trastuzumab emtansine 24 hours after the SRT. The combined effect of stereotactic radiation therapy on a metastatic lesion followed by anti-HER2 therapy in the 2nd line - trastuzumab emtansine, remains unexplored. This study plans to evaluate the effectiveness of combining systemic therapy and local control methods (SRT) in patients with oligometastatic HER2-positive breast cancer. It will be the first time the efficacy and toxic profile of this new combined treatment method in this patient population will be studied. This basket trial evaluates trastuzumab emtansine for oligo-metastatic breast cancer with the aim of inducing deep responses, long-lasting disease remissions, and potentially cure.
Detailed description
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who were treated with trastuzumab-emtansine and had a history of SRT. The dynamics of the process will be evaluated retrospectively using CT and MRI data according to RECIST 1.1 criteria. The main statistical indicators will be calculated based on the patients' medical documentation. The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT for up to 2 cycles, depending on the location of the irradiated focus, followed by administration of trastuzumab emtansine 3.6 mcg/kg once every 3 weeks, up to 4 total cycles. Trastuzumab emtansine therapy will be initiated 24 hours after the end of the course of SRT. Tumor foci will be assessed according to RECIST 1.1 criteria. Objective response, general condition, and adverse events will be evaluated before, during, and after treatment. Patients will be stratified by age, location of metastatic foci, and treatment. Outpatient patient records, medical histories, clinical and laboratory examination data, morphological examination data, CT findings, MRI findings will be used as sources of information for analyzing the results of diagnosis and treatment.
Interventions
DRUGTrastuzumab emtansine
SRT for metastatic foci
Sponsors
N.N. Petrov National Medical Research Center of Oncology
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must be at least 18 years of age and able to give written informed consent and comply with study procedures; 2. Clinical diagnosis: breast cancer, metastatic form; 3. Oligo-metastatic disease as determined by standard of care diagnostics, limited to 5 total individual distant metastases, either in one organ or in 2-3 organ systems. Clustered lymph nodes that can be irradiated with curative intent in a single field are defined as single lesion; 4. Possibility of complete elimination of all foci; 5. HER2 expression level of 3+ points according to immunohistochemical analysis (IHC) and/or degree of amplification ≥2.0 according to the results of in situ hybridization (ISH); 6. Patients with stable metastatic brain foci for at least 4-6 weeks (according to MRI); 7. Patients with HER2+ inoperable locally advanced or metastatic breast cancer who previously received taxanes and trastuzumab; 8. ECOG 0-1 status; 9. Life expectancy of more than 6 months.
Exclusion criteria
1. T-DM1 therapy in the medical history; 2. Autoimmune diseases in the medical history or treatment of exacerbations during the last three months; 3. Uncontrolled brain metastases and/or carcinomatous meningitis, causing neurological symptoms; 4. Primary multiple malignant tumors: other malignant neoplasms requiring active treatment; 5. Acute myocardial infarction, acute cerebrovascular accident, uncorrectable coagulopathy, decompensated concomitant pathology, infectious diseases in the active phase, ECOG status \> 2; 6. Pregnancy, lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | 3 month | Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as determined by investigator assessment, per RECIST 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 6 month | Progression free survival (PFS) is defined as the time from the start of study treatment until the disease progression or death. |
| Toxicity profile | 3 month | The assessment of adverse events will be carried out according to the STS AE v.5.0 system. |
| Second co-primary outcome measure is quality of life | 3 month | of Cancer (EORTC) Quality of Life Questionnaire for Cancer patients with 30 items (QLQ-C30) sum score |
Countries
Russia
Contacts
Primary ContactTatiana Semiglazova, DSc Med., Prof.
Backup ContactTatiana Kudryashova
Outcome results
None listed